San Antonio Breast Cancer Symposium (SABCS) is coming soon (December 7-10, 2021). People living with MBC can attend SABCS and other conferences to learn about the...
Inflammatory breast cancer is rare, making up only 1-5% of cases of breast cancer in the US. Inflammatory breast cancer does not always involve a lump, and...
Lack of diversity is a long-standing issue in clinical trials. This lack of diversity is often related to strict eligibility criteria, including other medications...
The European Society for Medical Oncology (ESMO) was held virtually from September 16-21, 2021. Links to MBC-related news from this conference are found below....
Our newest Metastatic Trial Search partner is the Tigerlily Foundation. Tigerlily educates, advocates for, empowers, and supports young women diagnosed with...
A cancer diagnosis is a life-changing event. It not only impacts health, it can also affect every aspect of one’s life, including finances, insurance,...
Atezolizumab (Tecentriq®) was the first FDA-approved immunotherapy for treating locally advanced or metastatic triple-negative breast cancer (TNBC). It is for...